Paper Review Records
All Paper Review Records
20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
100
days
Spatial and Temporal Heterogeneity of Macrophage Efferocytosis in Tumors: Emerging Implications for Immunotherapy Biomarkers and Therapeutic Timing
AuthorsShanyi Li; Jilei Li; Zhenyu Zhang; Sizhe Wang; Chunzheng Ma
Affiliations1. Henan University of Chinese Medicine Zhengzhou China; 2. Henan Provincial Hospital of Traditional Chinese Medicine Zhengzhou China
211
days
Cancer Patients Mortality From Other Causes: A European Population‐Based Study
AuthorsGemma Gatta; Riccardo Capocaccia; Silvia Rossi; Maria Athanasiadou; Damien Bennett; Ladislav Dusek; Jaume Galceran; Monica Hackl; Bernd Holleczek; Kaire Innos; Alexander Katalinic; Raphael Marcos‐Gragera; Deirdre Murray; Robin Schaffar; Stephanie Smits; Giedrė Smailytė; Hans Storm; Claudia Vener; Tina Žagar; Alice Bernasconi; Valerie Jooste; Laura Botta; the EUROCARE‐6 WG
Affiliations1. Università Milano Bicocca Milan Italy; 2. Editorial Board Epidemiologia e Prevenzione Milan Italy; 3. Department of Oncology and Molecular Medicine Istituto Superiore di Sanità Rome Italy; 4. Cyprus Ministry of Health Nicosia Cyprus; 5. Northern Ireland Cancer Registry Queen's University Belfast Belfast UK; 6. Biostatistics and Analysis Institute Masarykova University Brno Czech Republic; 7. Epidemiology and Prevention Cancer Service Hospital Universitari Sant Joan de Reus, IISPV Reus Spain; 8. Austrian National Cancer Registry Wien Austria; 9. Saarland Cancer Registry Saarbrücken Germany; 10. National Institute for Health Development Tallin Estonia; 11. Institute of Social Medicine and Epidemiology University of Lubeck Lübeck Germany; 12. Girona Cancer Registry Catalan Institute of Oncology Girona Spain; 13. National Cancer Registry Ireland and Department of Public Health University College Cork Cork Ireland; 14. Geneva Cancer Registry, Institute of Global Health, Faculty of Medicine University of Geneva Geneva Switzerland; 15. Welsh Cancer Intelligence and Surveillance Unit Public Health Wales Cardiff UK; 16. Lithuania National CR, Institute of Oncology Vilnius University Vilnius Lithuania; 17. Danish Cancer Society Copenhagen Denmark; 18. Epidemiology and Prevention Unit Fondazione IRCCS Istituto Nazionale Dei Tumori Milan Italy; 19. Slovenian Cancer Registry Institute of Oncology Ljubljana Ljubljana Slovenia; 20. Digestive Cancer Registry of Burgundy Dijon Dijon France; 21. Centre Hospitalier Universitaire (CHU) Dijon Bourgogne Dijon France; 22. CTM Research Center—UMR1231, Institut National de la Santé et de la Recherche Médicale (INSERM) Dijon France; 23. Université Bourgogne Europe Dijon France
69
days
The Impact of Upfront DihydroPyrimidine Dehydrogenase ( DPD ) Testing on the Therapeutic Management of Patients Scheduled for 5‐ FU
AuthorsGovind Kallee; Sébastien Salas; Gérard Milano; Florence Duffaud; Laetitia Dahan; Joseph Ciccolini
Affiliations1. PRISM, Biogenopôle La Timone University Hospital of Marseille, APHM Marseille France; 2. COMPO, Inserm U1068, CRCM, Aix Marseille Univ, Institut Paoli Calmettes, INRIA Sophia Antipolis & Marseille Marseille France; 3. Medical Oncology La Timone University Hospital of Marseille, APHM Marseille France; 4. Scientific Direction, Centre Antoine Lacassagne Nice France; 5. Digestive Oncology La Timone University Hospital of Marseille, APHM Marseille France
567
days
Ethnic Differences in Unmet Care Needs Among Cancer Survivors in Utah Using a Mixed Methods Approach
AuthorsSara G. Jackson; Anne C. Kirchhoff; Sandra L. Edwards; Kimberly A. Herget; Marjorie E. Carter; Rachel R. Codden; Blessing S. Ofori‐Atta; Marie Nagata; Carol Sweeney; Morgan M. Millar
Affiliations1. College of Nursing University of Utah Salt Lake City Utah USA; 2. Department of Pediatrics University of Utah School of Medicine Salt Lake City Utah USA; 3. Cancer Control and Population Sciences Program, Huntsman Cancer Institute University of Utah School of Medicine Salt Lake City Utah USA; 4. Utah Cancer Registry University of Utah School of Medicine Salt Lake City Utah USA; 5. Division of Epidemiology, Department of Internal Medicine University of Utah School of Medicine Salt Lake City Utah USA; 6. Utah Department of Health and Human Services Salt Lake City Utah USA
298
days
Phase Ib Trial of Finotonlimab Combined With SCT200 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
AuthorsJinguan Lin; Song Qu; Kunyu Yang; Tao Zhang; Yuansong Bai; Jian Wu; Yanjing Huang; Meiyu Fang; Xianling Liu; Xiaoming Huang; Nianyong Chen; Zhendong Li; Weidong Li; Songnan Zhang; Shurong Zhang; Guangyuan Hu; Yan Sun; Xiaohong Chen; Yanyan Liu; Shanghua Jing; Liangfang Shen; Zhiwei Chang; Liangzhi Xie; Wenlin Gai; Yan Wang; Xinyue Chen; Dongfang Liu; Ye Guo
Affiliations1. The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University/Hunan Cancer Hospital Changsha China; 2. Guangxi Medical University Cancer Hospital Nanning China; 3. Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China; 4. The First Affiliated Hospital of Chongqing Medical University Chongqing China; 5. The Third Bethune Hospital of Jilin University Changchun China; 6. Chongqing University Cancer Hospital Chongqing China; 7. Hainan General Hospital Haikou China; 8. Zhejiang Cancer Hospital Hangzhou China; 9. The Second Xiangya Hospital of Central South University Changsha China; 10. Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou China; 11. West China Hospital Sichuan University Chengdu China; 12. Liaoning Cancer Hospital & Institute Shenyang China; 13. Affiliated Cancer Hospital and Institute of Guangzhou Medical University Guangzhou China; 14. Yanbian University Hospital Yanji China; 15. Beijing Tongren Hospital Affiliated to Capital Medical University Beijing China; 16. Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China; 17. Peking University Cancer Hospital Beijing China; 18. Henan Cancer Hospital Zhengzhou China; 19. The Fourth Hospital of Hebei Medical University Shijiazhuang China; 20. Xiangya Hospital of Central South University Changsha China; 21. The First Affiliated Hospital of Zhengzhou University Zhengzhou China; 22. Beijing Engineering Research Center of Protein and Antibody Sinocelltech Ltd. Beijing China; 23. Shanghai East Hospital, School of Medicine Tongji University Shanghai China
257
days
Construction and Validation of a Progression‐Free Survival Prediction Model for Newly Diagnosed Multiple Myeloma Patients With 1q21 Gain/Amplification
AuthorsYuexuan Rao; Shiyou Li; Aoyang Yu; Wenjie Yu; Zhiyuan Yao; Huanxin Zhang; Zhenyu Li
Affiliations1. Department of Hematology Affiliated Hospital of Xuzhou Medical University Xuzhou Jiangsu Province China; 2. The First Clinical College of Xuzhou Medical University Xuzhou Jiangsu Province China
423
days
Telenursing to Improve Quality of Life in Women With Breast Cancer: A Systematic Review and Meta‐Analysis
AuthorsSerena Ricchiuto; Diego Lopane; Stefano Mancin; Daniela Cattani; Alessandra Dacomi; Simone Cosmai; Mattia Bozzetti; Beatrice Mazzoleni
Affiliations1. Humanitas University Milan Italy; 2. IRCCS Humanitas Research Hospital Milan Italy; 3. Department of Biomedical Sciences Humanitas University Milan Italy; 4. Direction of Health Professions, ASST Cremona Italy
137
days
Prognostic Value of Hemoglobin, Albumin, Lymphocyte, and Platelet Score in Locally Advanced Nasopharyngeal Carcinoma
AuthorsJunMei Song; Lan Luo; Ting Liu; YuQing Lv; Qiulin Huang; Rensheng Wang; Jun Bie
Affiliations1. Oncology Department Beijing Anzhen Nanchong Hospital, Capital Medical University (Nanchong Central Hospital) Nanchong Sichuan China; 2. The Second Clinical Medical College of North Sichuan Medical College Nanchong Sichuan China; 3. Department of Radiation Oncology The First Affiliated Hospital of Guangxi Medical University Nanning Guangxi China; 4. Oncology Department The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine (Xianhu District) Nanning Guangxi China; 5. Second Division of Department of Radiation Oncology Guangxi Academy of Medical, Sciences & The People's Hospital of Guangxi Zhuang Autonomous Region Nanning Guangxi China
226
days
Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin
AuthorsKunihiro Odagiri; Toshiharu Morikawa; Taku Naiki; Yosuke Sugiyama; Yoshihiko Tasaki; Yoshihisa Mimura; Aya Naiki‐Ito; Takashi Nagai; Toshiki Etani; Keitaro Iida; Daiki Ishikawa; Yusuke Noda; Nobuhiko Shimizu; Maria Aoki; Masakazu Gonda; Rika Banno; Hiroki Kubota; Ryosuke Ando; Yukihiro Umemoto; Noriyasu Kawai; Yoko Furukawa‐Hibi; Takahiro Yasui
Affiliations1. Department of Clinical Pharmaceutics Nagoya City University Graduate School of Medical Sciences Nagoya Aichi Japan; 2. Department of Nephro‐urology Nagoya City University Graduate School of Medical Sciences Nagoya Aichi Japan; 3. Department of Urology Nagoya City University West Medical Center Nagoya Aichi Japan; 4. Department of Experimental Pathology and Tumor Biology Nagoya City University Graduate School of Medical Sciences Nagoya Aichi Japan; 5. Department of Urology Anjo Kosei Hospital Anjo Aichi Japan; 6. Department of Urology Konan Kosei Hospital Konan Aichi Japan; 7. Department of Urology Kainan Hospital Yatomi Aichi Japan
372
days
Effect of Tertiary Lymphoid Structures on Immune Cell Infiltration in the Tumor Microenvironment and Prognosis in Lung Adenocarcinoma
AuthorsSihong Le; Weidan Fang; Yitao Le; Ling Zhang
Affiliations1. Department of Oncology The First Affiliated Hospital, Jiangxi Medical College, Nanchang University Nanchang China; 2. Department of Urology The First Affiliated Hospital, Jiangxi Medical College, Nanchang University Nanchang China
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days